Access to previously inaccessible tissue that would have only been available post-mortem |
Wide variability has been noted in brain organoids cultured under identical conditions |
Contain same genetic background as patients in case of iPSC-derived organoids |
No standardized protocol for establishing organoid models – Which protocol is the right protocol? |
In instances where iPSCs are unavailable, researchers can use genome editing to introduce disease-associated mutations in stem cells to derive organoids |
Difficulty in modeling interacting systems requiring organoids to be cultured under different conditions. Trans-well culture systems developed, but prevent direct physical interaction, which may be required |
Preponderance of protocols to derive various organoids that can be scaled up or down depending on laboratory capabilities |
No established methodology to introduce functional vascularization into brain organoids, short of engrafting the organoids into rodent hosts |
Provides a more “in vivo” like human cellular model for drug screening |
Cultures are more representative of fetal developmental stages rather than postnatal stages |
3D microenvironment that more faithfully recapitulates cell-cell interactions than 2D models |
Clonal variability, even among iPSCs from the same patient, requires the use of multiple clones to generate organoids |